1029439-83-5Relevant academic research and scientific papers
BIARYL DERIVATIVE AS GPR120 AGONIST
-
, (2017/11/17)
The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.
HEPATITIS B CORE PROTEIN MODULATORS
-
Paragraph 000127, (2017/04/11)
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
Discovery of Potent and Selective RSK Inhibitors as Biological Probes
Jain, Rama,Mathur, Michelle,Lan, Jiong,Costales, Abran,Atallah, Gordana,Ramurthy, Savithri,Subramanian, Sharadha,Setti, Lina,Feucht, Paul,Warne, Bob,Doyle, Laura,Basham, Stephen,Jefferson, Anne B.,Lindvall, Mika,Appleton, Brent A.,Shafer, Cynthia M.
, p. 6766 - 6783 (2015/09/22)
While the p90 ribosomal S6 kinase (RSK) family has been implicated in multiple tumor cell functions, the full understanding of this kinase family has been restricted by the lack of highly selective inhibitors. A bis-phenol pyrazole was identified from hig
BIARYL DERIVATIVES AS GPR120 AGONISTS
-
, (2015/01/16)
The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.
Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton
Mita, Yusuke,Noguchi-Yachide, Tomomi,Ishikawa, Minoru,Hashimoto, Yuichi
, p. 608 - 617 (2013/02/25)
Polo-like kinase (Plk) 1 is a serine-threonine protein kinase that plays a role in cell division, and its overexpression is highly correlated with aggressiveness and prognosis of many cancers. We have designed, synthesized and evaluated a series of terphe
